Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
biotech · Pulmonary Disease, Chronic Obstructive · Symptomatic Neurogenic Orthostatic Hypertension · TBPH
Theravance Biopharma Ireland
Theravance Biopharma Ireland Umited
Theravance Biopharma Ireland drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
901 Gateway Blvd., South San Francisco, CA 94080, US HQ
2014 Founded
177 Employees
Public company Type
TBPH · NYSE Ticker
Company details
- Status
- Public
- HQ
- 901 Gateway Blvd., South San Francisco, CA 94080, US
- Founded
- 2014
- Employees
- 177
- Programs
- 57
- Drugs
- 18
- Patents
- 635
Theravance Biopharma Ireland pipeline
Portfolio lens on 18 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Theravance Biopharma Ireland drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
telavancin
Antiinfectives for systemic use (J01)US regulatory status: approved.
-
umeclidinium
Respiratory system (R03)Respiratory system (R03) compound in Theravance Biopharma Ireland's portfolio. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.